Temozolomide use in elderly patients with MGMT promoter unmethylated glioblastoma: Is it finally time to dismount a dead horse?
作者信息
Sener Ugur T, Sulman Erik P, Sarkaria Jann N
机构信息
Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Neuro Oncol. 2024 Oct 3;26(10):1876-1877. doi: 10.1093/neuonc/noae143.
Abstract
摘要
相似文献
1
Temozolomide use in elderly patients with MGMT promoter unmethylated glioblastoma: Is it finally time to dismount a dead horse?替莫唑胺在O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子未甲基化的老年胶质母细胞瘤患者中的应用：是否终于到了放弃一匹死马的时候？
Neuro Oncol. 2024 Oct 3;26(10):1876-1877. doi: 10.1093/neuonc/noae143.
2
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?胶质母细胞瘤患者中，若其O⁶-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子未甲基化，是否停用替莫唑胺——这仍是一个两难问题？
Neuro Oncol. 2015 Nov;17(11):1425-7. doi: 10.1093/neuonc/nov198. Epub 2015 Sep 15.
3
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化与儿童胶质母细胞瘤的生存获益及对替莫唑胺的敏感性相关。
Pediatr Blood Cancer. 2007 Apr;48(4):403-7. doi: 10.1002/pbc.20803.
4
Treatment considerations for MGMT-unmethylated glioblastoma.MGMT 未甲基化胶质母细胞瘤的治疗考虑因素。
Curr Neurol Neurosci Rep. 2015 Jan;15(1):507. doi: 10.1007/s11910-014-0507-z.
5
Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.老年胶质母细胞瘤患者的治疗：系统循证分析。
JAMA Neurol. 2015 May;72(5):589-96. doi: 10.1001/jamaneurol.2014.3739.
6
To Use or Not to Use: Temozolomide in Elderly Patients with IDH Wild-Type MGMT Promoter Unmethylated Glioblastoma Treated with Radiotherapy.用还是不用：替莫唑胺用于接受放疗的异柠檬酸脱氢酶野生型、O6-甲基鸟嘌呤-DNA甲基转移酶启动子未甲基化的老年胶质母细胞瘤患者
Cancer Res Treat. 2025 Jul;57(3):693-700. doi: 10.4143/crt.2024.945. Epub 2024 Nov 11.
7
MGMT methylation in glioblastoma: tale of the tail.胶质母细胞瘤中的MGMT甲基化：尾之 tale 。 （这里“tale of the tail”字面直译为“尾巴的故事”，放在医学语境中可能需要结合更专业知识理解其确切含义，整体译文按要求进行了直接翻译）
Neuro Oncol. 2015 Jan;17(1):167-8. doi: 10.1093/neuonc/nou319. Epub 2014 Nov 13.
8
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.胶质母细胞瘤中连续样本中O(6)-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化的变化
J Neurooncol. 2008 Mar;87(1):71-8. doi: 10.1007/s11060-007-9486-0. Epub 2007 Nov 15.
9
Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?老年新诊断的胶质母细胞瘤：何时单独使用替莫唑胺就足够了？
Neuro Oncol. 2020 Aug 17;22(8):1058-1059. doi: 10.1093/neuonc/noaa136.
10
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.原位胶质母细胞瘤异种移植模型中MGMT启动子甲基化状态的评估及其与替莫唑胺反应的相关性
J Neurooncol. 2009 Mar;92(1):23-31. doi: 10.1007/s11060-008-9737-8. Epub 2008 Nov 15.
引用本文的文献
1
Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT).通过体外药物筛选实现胶质母细胞瘤个性化靶向治疗：高级脑肿瘤治疗临床试验（ATTRACT）研究方案
Neurooncol Adv. 2025 Mar 7;7(1):vdaf056. doi: 10.1093/noajnl/vdaf056. eCollection 2025 Jan-Dec.
2
Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance.肿瘤异质性、免疫逃逸和治疗抗性交汇处的胶质母细胞瘤干细胞
Cells. 2025 Apr 9;14(8):562. doi: 10.3390/cells14080562.
本文引用的文献
1
No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients.特罗凯治疗 MGMT 启动子未甲基化的胶质母细胞瘤无效：老年胶质母细胞瘤患者 CE.6 和北欧/NOA-08 试验的再分析。
Neuro Oncol. 2024 Oct 3;26(10):1867-1875. doi: 10.1093/neuonc/noae108.
2
MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value.胶质母细胞瘤的长期和短期幸存者的 MGMT 甲基化模式显示增强子区域的 CpG 具有高预后价值。
Acta Neuropathol Commun. 2023 Aug 28;11(1):139. doi: 10.1186/s40478-023-01622-w.
3
Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.预测 IDH 野生型胶质母细胞瘤患者同质队列中的 MGMT 状态。
Acta Neuropathol Commun. 2019 Jun 5;7(1):89. doi: 10.1186/s40478-019-0745-z.
4
Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.有安全边际的启动子甲基化临界值选择胶质母细胞瘤患者入组避免替莫唑胺治疗的临床试验：四项临床试验的汇总分析。
Clin Cancer Res. 2019 Mar 15;25(6):1809-1816. doi: 10.1158/1078-0432.CCR-18-3181. Epub 2018 Dec 4.
5
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.短程放疗联合替莫唑胺治疗老年胶质母细胞瘤患者。
N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.
6
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.替莫唑胺对比标准 6 周放疗对比低分割放疗用于 60 岁以上胶质母细胞瘤患者：北欧随机 3 期试验。
Lancet Oncol. 2012 Sep;13(9):916-26. doi: 10.1016/S1470-2045(12)70265-6. Epub 2012 Aug 8.
7
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.替莫唑胺化疗单独与单独放疗治疗老年恶性星形细胞瘤的比较：NOA-08 随机、3 期试验。
Lancet Oncol. 2012 Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub 2012 May 10.
8
MGMT gene silencing and benefit from temozolomide in glioblastoma.MGMT基因沉默与胶质母细胞瘤对替莫唑胺的获益
N Engl J Med. 2005 Mar 10;352(10):997-1003. doi: 10.1056/NEJMoa043331.
9
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.放疗联合同步及辅助替莫唑胺治疗胶质母细胞瘤
N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330.
Zotero 插件